Highlights Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse Other stock markets 04:00:02 2024-05-07 pm EDT			5-day change	1st Jan Change
5.35 ^USD	-0.74%		-3.95%	-71.39%

Apr. 30	Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating	MT
Apr. 29	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 29	MT
Top Midday Decliners	Apr. 29	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 29	MT
Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study	Apr. 29	MT
Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial	Apr. 29	RE
Annovis Bio, Inc. Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer?s Disease	Apr. 29	CI
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	Apr. 01	CI
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Top Midday Gainers	Mar. 20	MT
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	Mar. 20	CI
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million	Mar. 14	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease	Feb. 14	CI
Annovis Bio, Inc. Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company?s Portfolio	Jan. 30	CI
Annovis Bio, Inc. Refines Timeline for Parkinson's Phase III Study Data Announcement	Jan. 24	CI
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase III Study of Buntanetap in Parkinson?s Disease	Dec. 05	CI
Annovis Bio, Inc. Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projects	Nov. 27	CI
Annovis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Annovis Bio, Inc. Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer?s Disease Patients From the Independent Data and Safety Monitoring Board	23-10-30	CI
Annovis Bio, Inc. Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference	23-10-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Highlights

Filters